Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics Inc (NQ: PLRX )

13.95 +0.07 (+0.50%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 357,044
Open 13.89
Bid (Size) 13.00 (1)
Ask (Size) 14.18 (1)
Prev. Close 13.88
Today's Range 13.64 - 14.05
52wk Range 10.29 - 20.23
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
From Pliant Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace

Performance

YTD
-22.33%
-22.33%
1 Month
+28.45%
+28.45%
3 Month
+18.02%
+18.02%
6 Month
-24.47%
-24.47%
1 Year
-21.80%
-21.80%

More News

Read More
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Pliant Therapeutics, Inc.
Via GlobeNewswire
These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 Earnings
Via Benzinga
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Via Benzinga
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
From Pliant Therapeutics, Inc.
Via GlobeNewswire
PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Events
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Why Is Liver Disease-Focused Pliant Therapeutics Stock Trading Lower Today?
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
Via Benzinga
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.